Tvardi Therapeutics (NASDAQ:TVRD) and Zura Bio (NASDAQ:ZURA) Financial Contrast

Tvardi Therapeutics (NASDAQ:TVRD) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Risk and Volatility

Tvardi Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500.

Profitability

This table compares Tvardi Therapeutics and Zura Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-64.17%	-43.90%
Zura Bio	N/A	-55.74%	-48.07%

Insider & Institutional Ownership

44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by insiders. Comparatively, 12.4% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Tvardi Therapeutics and Zura Bio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14 million	4.05	-$18.21 million	($3.10)	-0.99
Zura Bio	N/A	N/A	-$99.35 million	($1.09)	-4.82

Tvardi Therapeutics has higher revenue and earnings than Zura Bio. Zura Bio is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Tvardi Therapeutics and Zura Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1	1	6	1	2.78
Zura Bio	1	1	4	1	2.71

Tvardi Therapeutics currently has a consensus price target of $19.67, suggesting a potential upside of 538.53%. Zura Bio has a consensus price target of $10.75, suggesting a potential upside of 104.76%. Given Tvardi Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Tvardi Therapeutics is more favorable than Zura Bio.

Summary

Tvardi Therapeutics beats Zura Bio on 8 of the 12 factors compared between the two stocks.

About Tvardi Therapeutics

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.